

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Garvey et al**

Serial No.: **Not Yet Assigned**

Filing Date: **December 21, 2001**

Title: **Nitrosated and Nitrosylated Alpha-Adrenergic Receptor
Antagonist Compounds, Compositions and Their Uses**

Docket Number: **102258.346 US2**

ATTN: BOX PATENT APPLICATION

Assistant Commissioner for Patents
Washington, DC 20231

TRANSMITTAL LETTER

Enclosed herewith for filing in the United States Patent and Trademark Office for the above-referenced application are the following documents:

1. United States Patent Application claiming priority to:

US Application No. 09/478,222 filed January 5, 2000, pending;
US Application No. 09/145,143 filed September 1, 1998, issued as US 6,294,517;
US Application No. 08/714,313 filed September 18, 1996, issued as US 5,994,294;
US Application No. 08/595,732 filed February 2, 1996, issued as US 5,932,538; and
PCT/US97/01294, filed January 28, 1997;

naming as inventors: David S. Garvey and Inigo Saenz de Tejada

the application having 96 pages which include:

73 pages of specification;
15 pages of claims;
1 page of abstract; and
7 pages of drawings.

2. Copy of the executed Declaration and Power of Attorney signed by the inventors in parent Application No. 09/145,143;

3. Statement under 37 C.F.R. § 1.63(d)(2).

4. Preliminary Amendment;

5. Return postcard.

Pursuant to 37 C.F.R. § 1.28(a)(2), small entity status was established in parent Application No. 09/145,143 and small entity status is still proper and desired in the present application.

After entry of the Preliminary Amendment, the fee is calculated as follows:

Claims		Extra Claims	Small Entity Fee per Claim	Small Entity Fee Paid
2 Total	- 20	0	x \$9	\$0
2 Independent	- 3	0	x \$39	\$0
Small Entity Filing Fee				\$370

TOTAL FEE DUE:

\$370

The Commissioner is authorized to charge the fee of **\$370** to Deposit Account No. 08-0219, and to charge any other fees or credit any overpayments to Deposit Account No. 08-0219 to maintain the pendency of the present application.

Please direct all correspondence in this application to:



25270

PATENT TRADEMARK OFFICE

Edward D. Grieff, Esq.
Hale and Dorr LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004

Respectfully submitted,

Edward D. Grieff
Registration No. 38,898

Date: December 21, 2001
Hale and Dorr LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: 202-942-8453

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Garvey et al**

Serial No.: **Not Yet Assigned**

Filing Date: **December 21, 2001**

Title: **Nitrosated and Nitrosylated Alpha-Adrenergic Receptor
Antagonist Compounds, Compositions and Their Uses**

Attorney Docket No: **102258.346 US2**


Assistant Commissioner of Patents
Washington, DC 20231

STATEMENT UNDER 37 C.F.R. §1.63(d)(2)

Pursuant to 37 C.F.R. §1.63(d)(2), it is requested that Joseph D. Schroeder be deleted as an inventor from the application filed herewith. After entry of the Preliminary Amendment filed concurrently herewith, Joseph D. Schroeder is not an inventor of the claimed matter.

Pursuant to 37 C.F.R. §1.33(b), the undersigned is authorized to delete the name of a person who is not an inventor of the claimed invention in a continuation or divisional application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Edward D. Grieff", followed by a large, stylized circular flourish or scribble.

Edward D. Grieff
Registration No. 38,898

Date: December 21, 2001

HALE and DORR LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: 202-942-8453